We read with great interest the paper by Ludwig and Zojer reporting a patient with bortezomib-resistant multiple myeloma who achieved renal recovery after lenalidomide therapy. A similar case was reported in 2009 by Layzer and Wolf in a patient with multiple myeloma and refractory polyneuropathy whose condition significantly improved after treatment with lenalidomide.The reduced neurotoxic effect of lenalidomide compared with thalidomide is well known, and results from a retrospective study reported that six of nine patients with bortezomib-induced neuropathy had symptomatic improvement after therapy with lenalidomide. In line with these encouraging data, we would like to share our group’s preliminary experience with lenalidomide in patients with chemotherapy-induced peripheral neuropathy (CIPN).
Lenalidomide for bortezomib- resistant Multiple Myeloma
BRIANI, CHIARA;CAMPAGNOLO M;ZAMBELLO R.
2010
Abstract
We read with great interest the paper by Ludwig and Zojer reporting a patient with bortezomib-resistant multiple myeloma who achieved renal recovery after lenalidomide therapy. A similar case was reported in 2009 by Layzer and Wolf in a patient with multiple myeloma and refractory polyneuropathy whose condition significantly improved after treatment with lenalidomide.The reduced neurotoxic effect of lenalidomide compared with thalidomide is well known, and results from a retrospective study reported that six of nine patients with bortezomib-induced neuropathy had symptomatic improvement after therapy with lenalidomide. In line with these encouraging data, we would like to share our group’s preliminary experience with lenalidomide in patients with chemotherapy-induced peripheral neuropathy (CIPN).Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
